Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Simple Summary The current meta-analysis highlighted that proton pump inhibitors (PPIs)
and histamine-2-receptor antagonists (H2RAs) could impact immune checkpoint inhibitors …

The use of immune checkpoint inhibitors (ICIs) has become one of the most promising
approaches in the field of cancer therapy. Unlike the current therapies that target tumor cells …

Non-small cell lung cancer is one of the most common types of malignances worldwide and
the main cause of cancer-related deaths. Current treatment for NSCLC is based on surgical …

Tumor-infiltrating immune cells are closely associated with clinical outcome. However,
immunohistochemistry-based analysis of tumor infiltrates can be misleading as the …

In the last 20 years, an increasing number of studies have been reported on membrane
active peptides. These peptides exert their biological activity by interacting with the cell …

Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the
leading causes of cancer-related death worldwide. Despite many therapeutic advances in …

A few years ago the answer to the question in the title of this review would have
been,“unfortunately not much” or even “nothing”, likely eliciting knowing nods of agreement …

Tumor microenvironment (TME) plays a crucial role in the initiation and progression of lung
adenocarcinoma (LUAD); however, there is still a challenge in understanding the dynamic …

Background Biomarkers for predicting the effect of anti–programmed cell death 1 (PD-1)
monoclonal antibody against non–small-cell lung cancer (NSCLC) are urgently required …